- Home
- CHRS vs TEAF Comparison
CHRS vs TEAF Comparison
Compare CHRS & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- TEAF
- Stock Information
- Founded
- CHRS 2010
- TEAF 2017
- Country
- CHRS United States
- TEAF United States
- Employees
- CHRS 235
- TEAF N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- TEAF Trusts Except Educational Religious and Charitable
- Sector
- CHRS Health Care
- TEAF Finance
- Exchange
- CHRS Nasdaq
- TEAF Nasdaq
- Market Cap
- CHRS 134.4M
- TEAF 174.8M
- IPO Year
- CHRS 2014
- TEAF N/A
- Fundamental
- Price
- CHRS $1.16
- TEAF $12.13
- Analyst Decision
- CHRS Strong Buy
- TEAF
- Analyst Count
- CHRS 4
- TEAF 0
- Target Price
- CHRS $5.38
- TEAF N/A
- AVG Volume (30 Days)
- CHRS 2.4M
- TEAF 56.1K
- Earning Date
- CHRS 03-12-2025
- TEAF 01-01-0001
- Dividend Yield
- CHRS N/A
- TEAF 9.20%
- EPS Growth
- CHRS N/A
- TEAF N/A
- EPS
- CHRS N/A
- TEAF N/A
- Revenue
- CHRS $304,340,000.00
- TEAF N/A
- Revenue This Year
- CHRS $2.47
- TEAF N/A
- Revenue Next Year
- CHRS N/A
- TEAF N/A
- P/E Ratio
- CHRS N/A
- TEAF N/A
- Revenue Growth
- CHRS 44.19
- TEAF N/A
- 52 Week Low
- CHRS $0.66
- TEAF $11.11
- 52 Week High
- CHRS $2.87
- TEAF $13.30
- Technical
- Relative Strength Index (RSI)
- CHRS 38.01
- TEAF 48.20
- Support Level
- CHRS $1.03
- TEAF $12.05
- Resistance Level
- CHRS $1.39
- TEAF $12.20
- Average True Range (ATR)
- CHRS 0.14
- TEAF 0.14
- MACD
- CHRS -0.03
- TEAF 0.01
- Stochastic Oscillator
- CHRS 14.04
- TEAF 45.76
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.